Investor Relations

Investor Relations

Invest in Quadrant Biosciences

We’ve joined the fight against COVID-19, and you can help.

Invest in Quadrant Biosciences

We’ve joined the fight against COVID-19, and you can help.

Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes, and quality of life.

-Rich Uhlig, Founder & CEO

The Clarifi® diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges.  Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, Clarifi ASD® recently launched commercially in the US.  It is the first of its kind saliva test for autism spectrum disorder.  Quadrant is currently involved in three COVID-19 related projects with SUNY Upstate Medical University.

Quadrant Biosciences company overview

Why invest in Quadrant Biosciences?

Global leaders in the development of saliva-based epigenetic diagnostics

We develop saliva-based, RNA diagnostic solutions for autism spectrum disorder, Parkinson’s disease, concussion injury, and surveillance solutions for COVID-19.  We recently launched Clarifi ASD®, the world’s first saliva test for autism.

Comprehensive COVID-19 testing projects

In response to the COVID-19 pandemic, we leveraged our expertise in RNA analysis and became actively engaged in several major COVID-19 testing projects that involve individual testing, group (pooled) surveillance testing, and municipal wastewater surveillance.

An experienced management team

We have assembled an experienced management team led by former Morgan Stanley Bank CEO Rich Uhlig, as well as an expert medical advisory board comprised of recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Quadrant Biosciences company overview

Want to learn more about Quadrant Biosciences?

Read more of our news stories and press releases.

Learn more about our published research.

Meet the team

We have assembled a seasoned management team, as well as an experienced clinical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.

What do our investors have to say about us?

Learn more about investing with us